|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7230012||CELGENE||Pharmaceutical compositions and dosage forms of thalidomide|| |
(2 months from now)
Thalomid is owned by Celgene.
Thalomid contains Thalidomide.
Thalomid has a total of 1 drug patent out of which 0 drug patents have expired.
Thalomid was authorised for market use on 16 July, 1998.
Thalomid is available in capsule;oral dosage forms.
The generics of Thalomid are possible to be released after 09 December, 2023.
Market Authorisation Date: 16 July, 1998
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic